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A metabolic interplay coordinated by HLX
regulates myeloid differentiation and AML through
partly overlapping pathways
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The H2.0-like homeobox transcription factor (HLX) regulates hematopoietic differentiation
and is overexpressed in Acute Myeloid Leukemia (AML), but the mechanisms underlying
these functions remain unclear. We demonstrate here that HLX overexpression leads to a
myeloid differentiation block both in zebraﬁsh and human hematopoietic stem and progenitor
cells (HSPCs). We show that HLX overexpression leads to downregulation of genes encoding
electron transport chain (ETC) components and upregulation of PPARδ gene expression in
zebraﬁsh and human HSPCs. HLX overexpression also results in AMPK activation. Phar-
macological modulation of PPARδ signaling relieves the HLX-induced myeloid differentiation
block and rescues HSPC loss upon HLX knockdown but it has no effect on AML cell lines. In
contrast, AMPK inhibition results in reduced viability of AML cell lines, but minimally affects
myeloid progenitors. This newly described role of HLX in regulating the metabolic state of
hematopoietic cells may have important therapeutic implications.
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Long-term hematopoietic stem cells (LT-HSCs) are multi-potent cells with self-renewal capacity primarily responsiblefor replenishing the entire hematopoietic system1–7. LT-
HSC differentiation into mature blood and immune cells is a
tightly regulated and multifaceted process. Transcription factors
govern the mechanisms that maintain the balance between LT-
HSC differentiation and self-renewal, or stemness8–10, and any
perturbation in this process can ultimately lead to disease.
While it is well established that homeobox (HOX) transcrip-
tion factors play a central role in hematopoietic development and
disease, less is known about the function of non-clustered HOX
factors in the hematopoietic system11,12. The non-clustered H2.0-
like homeobox transcription factor (HLX) has been recently
identiﬁed as an important regulator of hematopoiesis. During
development, HLX deﬁciency leads to a decrease in the colony-
forming capacity of fetal liver cells13–16, and in adult hemato-
poiesis HLX regulates Th1/Th2 differentiation during T-cell
development17–20. Recent evidence shows that HLX is essential
for HSC maintenance and self-renewal21–23. Increased expression
of HLX compromises self-renewal and eventually results in a
myelomonocytic differentiation block concomitant with aberrant
proliferation of myeloid progenitors21. Mechanistically, it has
been suggested that this function of HLX in HSC maintenance
and self-renewal is mediated by the p21-activated kinase PAK1.
Indeed, it was demonstrated that inhibition of HLX or PAK1
induces differentiation and apoptosis of AML cells21,22. Con-
sistent with this phenotype, HLX is overexpressed in 87% of AML
patients and those presenting higher HLX expression have lower
survival rates21. Recently, HLX has been shown to play a role in
the browning of white adipose tissue, suggesting that this tran-
scription factor is involved in the metabolic control of cell
differentiation24.
Despite the pleiotropic functions of HLX and its critical reg-
ulatory role in multiple processes, particularly in hematopoiesis,
only few direct downstream targets have been identiﬁed. More-
over, mechanistic insights into the function of HLX in hemato-
poiesis and myeloid differentiation are lacking. Thus,
understanding the physiological roles of HLX in hematopoietic
development and disease, including leukemia, remains a central
issue in HSC biology.
Here, we use zebraﬁsh, human hematopoietic stem and pro-
genitor cells (HSPCs), and AML cell lines to explore the under-
lying mechanisms of HLX function during hematopoiesis. We
show that HLX overexpression results in an aberrant proliferation
of HSPCs and a myeloid differentiation block in both systems.
We ﬁnd that HLX exerts its biological function in hematopoiesis,
at least in part, by direct control of electron transport chain
(ETC) and PPARδ gene expression. Metabolic stress leads to an
elevation of AMP-activated kinase (AMPK) levels and autophagy.
Modulation of PPARδ signaling can rescue the hematopoietic
phenotypes of HLX in both zebraﬁsh and human cells, but has no
obvious impact on AML cells. In contrast, AMPK inhibition
reduces viability of AML cell lines, but minimally affects primary
cells. This newly discovered link between HLX and metabolism
could be a promising new avenue for treating hematological
diseases.
Results
HLX overexpression blocks zebraﬁsh myeloid cell maturation.
To investigate the mechanisms underlying the role of HLX in
promoting AML, we examined hematopoiesis in HLX-
overexpressing zebraﬁsh models. We crossed the Tg(ﬂi1a:
Gal4FF)ubs325 line with our Tg(UAS:HLX-GFP) to induce
expression of human HLX (hHLX) in endothelial and hema-
topoietic cells and named these ﬁsh ﬂi:hHLXOE. We chose to
use human HLX in an effort to demonstrate conservation and
translate our results into the human gene function. ﬂi:hHLX
overexpression led to increased speciﬁcation of HSPCs at 36 h
post fertilization (hpf) in the Aorta–Gonad–Mesonephros
region as shown by runx1 whole-mount in situ hybridization
(WISH) (Fig. 1a and Supplementary Fig. 1a). The increased
number of HSPCs led to increased rag1 staining in the thymus
at 96 hpf (Fig. 1b). WISH for the early myeloid marker pu.1
revealed that these transgenic ﬁsh presented an expansion
of myeloid progenitors (Fig. 1c). We then asked whether
HLX overexpression affects myeloid cell maturation.
May–Grünwald–Giemsa staining showed that ﬂi:hHLXOE
embryos have a signiﬁcantly larger proportion of immature
myeloid cells (75.5%) when compared to their wild-type
counterparts (35.3%) at 48 hpf (Fig. 1d). EdU staining
revealed hyperproliferation of endothelial cells, which may be
the underlying cause of the increased number of HSPCs
(Fig. 1e). This enhanced proliferation does not induce apoptosis
in ﬂi:hHLXOE embryos, as shown by TUNEL assay (Supple-
mentary Fig. 1b).
At 48 hpf most of the myeloid cells are derived from primitive/
prodeﬁnitive and not deﬁnitive hematopoiesis. To verify that the
differentiation block occurs in myeloid cells that arise from
HSPCs we crossed Tg(Mmu.Runx1:GAL4) ﬁsh to Tg(UAS:HLX-
GFP) and named the progeny Runx:hHLXOE. These ﬁsh express
hHLX only in HSPCs. In this model we show that more HSPCs
are speciﬁed at 26 hpf as indicated by runx1 staining, followed by
modestly elevated c-myb staining and mRNA expression at 3 dpf
(days post fertilization) (Supplementary Fig. 1c, d). We then
veriﬁed by May–Grünwald–Giemsa staining that at 5 dpf HLX
overexpression in HSPCs leads to a strong myeloid differentiation
block without affecting erythrocyte numbers (Fig. 1f). This result
was veriﬁed by qPCR and WISH for a panel of mature myeloid
markers and gata1 as a marker of erythroid differentiation
(Supplementary Fig. 1d, e).
Together, these results suggest that HLX overexpression results
in increased numbers of HSPCs and blocks myeloid cell
differentiation.
HLX is required for HSPC formation. To examine hemato-
poiesis in hlx1 knockdown animals, we generated hlx1 morphants
(hlx1MO) using a previously published translational morpho-
lino26. Inhibition of hlx1 translation in zebraﬁsh embryos
decreased the pool of HSPCs, as shown by runx1 and c-myb
WISH at 36 hpf, respectively (Fig. 1g and Supplementary Fig. 1a, f).
To quantify the number of HSPCs in hlx1MO animals, we
injected either the translational morpholino used in all experi-
ments, or a splicing morpholino26 in Tg(Runx:mCherry) ﬁsh27, a
line with ﬂuorescent HSPCs. The number of m-Cherry+ cells
(HSPCs) was signiﬁcantly decreased in both types of morphants
(Supplementary Fig. 1g). WISH for rag1 showed that hlx1MO
have fewer thymocytes at 96 hpf (Fig. 1g), when compared to the
control embryos. To exclude the possibility that HSPC loss is due
to arterial or vascular endothelial defects, we analyzed the
expression of arterial (ephrinB2α) and endothelial (kdrl) markers
in hlx1MO. In agreement with previous reports, deregulation of
hlx1 affects the identity of stack cells, but does not seem to have
severe effects on the cardinal vein (Supplementary Fig. 1h)26.
Additionally, TUNEL assays demonstrated that HSPC loss in
hlx1MO is not caused by apoptosis, whereas EdU staining showed
reduced proliferation of endothelial cells (Supplementary Fig. 1b,
and Fig. 1e, respectively).
We then attempted to rescue the morphant phenotype by
overexpressing hHLX in endothelial/hematopoietic (ﬂi:hHLX) or
hemogenic endothelial cells (Runx:hHLX). Remarkably, hHLX
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overexpression in both cell types rescued HSPC loss (Fig. 1h and
Supplementary Fig. 1i).
Collectively, these data show that HLX regulates the formation
of HSPCs.
HLX regulates genes involved in metabolism. To understand
the mechanisms of HLX function in hematopoiesis, we performed
RNA-Seq on FACS-sorted endothelial cells from ﬂi:hHLXOE (ﬂi:
kaede) and hlx1MO (kdrl:GFP) embryos at 48 hpf. Compared
with control embryos, we identiﬁed 2950 downregulated and
3419 upregulated genes that changed by more than two-fold
(negative binomial test (NBT), P < 0.05) in ﬂi:hHLXOE embryos
(Fig. 2a, Supplementary Fig. 2a, and Supplementary Data 1). On
the other hand, 942 genes were downregulated and 1162 genes
upregulated over two-fold (NBT, P < 0.05) in hlx1MO animals
(Fig. 2a, Supplementary Fig. 2a, and Supplementary Data 1).
Seventy-nine (8%, hypergeometric test (hg.t), P < 0.01) of the
downregulated genes in hlx1MO were inversely correlated in ﬂi:
hHLXOE. In total 869 genes were deregulated in both hlx1MO
and ﬂi:hHLXOE (hg.t, P < 2.27E-120). Next, to identify pathways
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deregulated upon hHLX overexpression or hlx1 knockdown, we
performed ingenuity pathway analysis (IPA), gene ontology, and
gene set enrichment analysis (GSEA) and created networks using
Cytoscape (Fig. 2b, Supplementary Fig. 2b, c, and Supplementary
Data 1). These analyses showed that HLX is a pleiotropic tran-
scription factor that regulates fundamental processes. Interest-
ingly, the two canonical pathways most affected by hHLX
overexpression were oxidative phosphorylation (OXPHOS)
(right-tailed Fisher Exact Test (rtFET), P < 3.16E-23) and mito-
chondrial dysfunction (rtFET, P < 1.99E-21, Fig. 2b and Supple-
mentary Data 1). GSEA also indicated that genes downregulated
in ﬂi:hHLXOE or deregulated in hlx1MO are associated with
changes in mediators of OXPHOS (Supplementary Fig. 2c).
Multiple genes of the mitochondrial ETC belonged to the above-
mentioned categories and were downregulated in ﬂi:hHLXOE
embryos (Supplementary Data 1). Gene deregulation detected by
RNA-Seq was conﬁrmed by qPCR in ﬂi:hHLXOE and Runx:
hHLXOE or hlx1MO embryos (Supplementary Fig. 2d–f). These
results suggest that HLX regulates mitochondrial metabolic genes.
This unexpected ﬁnding has important implications, as mito-
chondrial metabolism is essential for LT-HSCs stemness28,29 and
AML patients can present defects in mitochondrial metabolism30.
Consistent with the transcriptional deregulation observed in
the hlx1MO, we also detected differences in chromatin accessi-
bility, by performing ATAC-Seq in endothelial (kdrl:GFP) cells
sorted from control and hlx1MO embryos at 48 hpf. Using the
MACS2 (version 2.1.0) bdgdiff command with the default settings
we identiﬁed 16,409 peaks that were either lost or gained in
hlx1MO, when compared to wild-type siblings (Fig. 2c and
Supplementary Data 2). Using Genomic Regions Enrichment of
Annotations Tool (GREAT) analysis, we found that the majority
of peaks were located between 5 and 500 kB of the transcription
start site (TSS) and regulate a variety of processes (Supplementary
Fig. 3a and Supplementary Data 2). We used a nominal cut-off of
25 kb from the TSS and assigned the differential peaks to 6431
genes (Supplementary Data 2). IPA analysis of these genes
revealed that mitochondrial dysfunction (rtFET, P < 3.47E-09)
and OXPHOS (rtFET, P < 8.13E-08) were among the upper
enriched categories (Supplementary Data 2). To gain mechanistic
insights we performed footprinting analysis31 in control and
hlx1MO datasets and obtained 54,588 and 50,471 footprints,
respectively. Motif discovery revealed HOX motifs enriched in
control-only footprints and AP-1 motifs in hlx1MO-only
fooptrints (Supplementary Fig. 3b). To determine whether these
motifs were signiﬁcantly differentially footprinted between the
two datasets, we computed motif self-enrichments and co-
occurrence enrichments from speciﬁc footprint populations over
background occurrences computed from reciprocal datasets. This
analysis revealed loss of HOX motifs and gain of AP-1 motifs in
hlx1MO (co-occurrence enrichment computation z= 3.583 and
z= 13.241, respectively) (Supplementary Fig. 3c). Tn5 insertion
proﬁles at these sites revealed diverging proﬁles at footprinted
Hoxc9 and AP1 motifs (Student's t-test, Hoxc9 control speciﬁc
P= 2.9884E-34, AP-1 hlx1MO speciﬁc P= 1.24262E-37)
(Fig. 2d). Analysis of relative footprint occurrences to their
cognate datasets also revealed that Hoxc9 and AP-1 motifs were
more present in control and hlx1MO-speciﬁc footprints,
respectively (Supplementary Fig. 3d).
After integration of our RNA-Seq and ATAC-Seq data from
the hlx1MO, we identiﬁed 739 (35%, hg.t., P < 1.930E-62)
deregulated genes with changes in chromatin accessibility (Fig. 2e
and Supplementary Data 2). Comparison of the ATAC-Seq from
hlx1MO and RNA-Seq from ﬂi:hHLXOE embryos demonstrated
that 1963 (31%, hg.t., P < 3.082e-116) deregulated genes exhibited
differences in chromatin accessibility (Fig. 2e, Supplementary
Fig. 3e, and Supplementary Data 2). Interestingly, ETC genes that
were downregulated upon hHLX overexpression also showed
changes in chromatin accessibility in two different types of
ATAC-Seq analyses (whole region or sub-nucleosomal) (Fig. 2f
and Supplementary Data 2). Concomitantly, some ETC genes
showed upregulation of expression in hlx1MO (Fig. 2f).
Finally, ppardb (peroxisome-proliferator activated receptor δ)
also showed changes in chromatin accessibility in sub-
nucleosomal analysis (Fig. 2e and Supplementary Data 2).
Recently PPARδ, a regulator of metabolic functions, was shown
to be critical for LT-HSC stemness32. We therefore performed
qPCR for ppar genes in hxl1MO, ﬂi:hHLXOE, and Runx:
hHLXOE embryos. Indeed, the expression of the ppar receptors
was signiﬁcantly decreased in hxl1MO (Fig. 2g), but only pparda
and ppardb were increased in ﬂi:hHLXOE or Runx:hHLXOE
embryos (Fig. 2h, i).
Together, these data demonstrate that Hlx1 regulates the
expression of ETC and ppar genes in zebraﬁsh endothelial cells
and HSPCs.
PPARδ signaling rescues zebraﬁsh hematopoietic phenotypes.
The results above suggest that HLX regulates genes involved in
metabolism. To investigate this further, we asked whether HLX
modulation has any functional consequences for cell metabolism
in vivo. We assessed OXPHOS by seahorse metabolic ﬂux ana-
lysis, which measures oxygen consumption rate (OCR). These
experiments revealed that there is a reduction in spare respiratory
capacity in ﬂi:hHLXOE embryos (Fig. 3a). Given the transcrip-
tional deregulation of ETC genes upon hHLX overexpression, we
measured mitochondrial membrane potential by using tetra-
methylrhodamine ethyl ester perchlorate (TMRM). TMRM is a
dye that is sequestered in active mitochondria, and reﬂects the
ability of cells to produce ATP. As expected, although the total
mitochondrial mass was unchanged in ﬂi:hHLXOE embryos,
TMRM was signiﬁcantly lower (Fig. 3b). In contrast, TMRM was
higher in endothelial cells of hlx1MO, yet the total mitochondrial
Fig. 1 hlx1 regulates hematopoietic stem cell formation and myeloid cell maturation in zebraﬁsh. a–b Whole-mount in situ hybridization (WISH) for runx1
(a) and rag1 (b) in control or ﬂi:hHLXOE zebraﬁsh embryos at 36 or 96 hpf, respectively. Arrows indicate HSPCs. Numbers in the bottom right corner of
panels indicate the number of zebraﬁsh embryos with the indicated phenotype compared to the total number of zebraﬁsh analyzed. Quantiﬁcation of WISH
was performed using FIJI software and statistical signiﬁcance of three independent experiments in 12 zebraﬁsh embryos was evaluated by Student’s t-test,
*P < 0.05, **P < 0.01 (mean+ s.d.). c WISH for the early myeloid marker pu.1 in control or ﬂi:hHLXOE zebraﬁsh embryos at 48 hpf. Numbers and WISH
quantiﬁcation was performed as described above (n= 3, in total 12 ﬁsh, Student’s t-test, *P < 0.05, mean+ s.d.). d Zebraﬁsh caudal hematopoietic tissue
(CHT) smears stained with May–Grünwald–Giemsa stain in control or ﬂi:hHLXOE embryos at 48 hpf. On the right, cell number counts of the indicated cell
populations from 10 ﬁsh (n= 3, mean+ s.d., Student’s t-test, *P < 0.05). e EDU assay at 48 hpf in control, hlx1 morphants (hlx1MO) or ﬂi:hHLXOE zebraﬁsh
cells (n= 2). f Zebraﬁsh CHT smears stained with May–Grünwald–Giemsa stain in control or Runx:hHLXOE embryos at 5 dpf. On the right, cell number
counts of the indicated cell populations from 10 ﬁshes, in two independent experiments (mean+ s.d., Student’s t-test, **P < 0.01, ****P < 0.0001). g WISH
for runx1 and rag1 in control or hlx1MO embryos at 36 and 96 hpf, respectively. h Representative images of Tg(Runx:mCherry) embryos at 72 hpf, injected or
not with hlx1 morpholino and the indicated amounts of ﬂi:hHLX construct. Numbers of mCherry-positive HSPCs from each embryo are represented in the
graph (n= 10; mean+ s.d., Student’s t-test, *P < 0.05, ***P < 0.001)
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mass was slightly decreased (Fig. 3c). These data demonstrate that
HLX overexpression affects mediators of OXPHOS and mito-
chondrial membrane potential in zebraﬁsh in vivo.
As HLX regulates PPARδ gene transcription, a gene essential
for lipid metabolism33, and in some systems mitochondrial
biogenesis34, we assessed whether pharmacological modulation of
PPARδ can rescue defects in mitochondrial membrane potential
maintenance. Indeed, we were able to rescue TMRM levels by
using a speciﬁc PPARδ antagonist (GSK3787) in ﬂi:hHLXOE
embryos, accompanied by an increase in the mitochondrial mass
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(Fig. 3d). This PPARδ antagonist also elevated the TMRM of the
control cells, albeit to a lower extent. We then attempted to rescue
the HLX-induced hematopoietic phenotypes by modulating the
activity of PPARδ. First, we treated ﬂi:hHLXOE zebraﬁsh
embryos with a PPARδ antagonist (GSK3787) and examined
erythro-myeloid cells at 48 hpf. Pharmacological inhibition of
PPARδ signiﬁcantly reduced the number of immature myeloid
cells and partially rescued the myeloid block (Fig. 3e). Conversely,
a PPARδ agonist (L165,041) rescued HSPC loss in hlx1MO
embryos (Fig. 3f).
These results demonstrate that modulation of PPARδ rescues
HLX-induced defects in HSPC formation and myeloid cell
maturation.
HLX regulates ETC and PPAR genes in human cells. We next
addressed the physiological relevance of the interplay between
HLX and metabolic regulation in humans. From the database
BloodSpot35 and previously published data36,37, we conﬁrmed
that HLX is expressed in murine and human hematopoietic
progenitor cells, but also in mature myeloid lineages (Supple-
mentary Fig. 4a–c). Moreover, HLX is upregulated in AML
patient samples, as it has been previously published21 and
according to information from cBioportal (Supplementary
Fig. 4d). We next investigated whether AML patients show
similar transcriptional signatures to those of hHLXOE zebraﬁsh
embryos. We obtained data generated by the TCGA Research
Network (http://cancergenome.nih.gov/) from 193 AML patients.
Normalized gene expression data of 156 AML samples were used
for further analysis. We performed correlation analysis among all
genes with signiﬁcant expression (RSEM values >50) across all
patients and the HLX gene. We then did GO and IPA analyses
(Supplementary Data 3) in the HLX positively (Pearson Corre-
lation Coefﬁcient >0.4, 824 genes) and negatively (Pearson Cor-
relation Coefﬁcient <−0.4, 542 genes) correlated genes.
Consistent with the zebraﬁsh data, OXPHOS (rtFET, P < 0.0003),
mitochondrial dysfunction (rtFET, P < 0.0107), and other meta-
bolic categories were among the pathways that showed positive
correlation with HLX expression in AML patients in IPA analysis
(Supplementary Fig. 4e and Data 3). Interestingly, HLX expres-
sion in patients positively correlates with PPARδ expression
(Pearson Correlation Coefﬁcient 0.42) (Supplementary Data 3).
These genomic analyses in AML patients suggest that the role
of HLX in metabolic regulation is conserved in humans. To
identify genes that are directly regulated by HLX in human
hematopoietic cells, we performed ChIP-Seq in two mammalian
cell lines (chronic myelogenous leukemia CML: K562 and acute
myeloid leukemia-AML HL60) overexpressing a FLAG-tagged
version of hHLX (Supplementary Fig. 5a). In both cell lines, the
majority of HLX ChIP-Seq peaks fell in introns (48.7% in K562
and 50.2% in HL60) and 50–500 kb from the TSS (Supplementary
Fig. 5b). After assigning the peaks located within 5 kb of the TSS
to their corresponding genes, we found that HLX was bound to
2135 and 6838 genes in K562 and HL60 cells, respectively. 1689
genes were found in both cell lines (hg.t., P < 0) (Supplementary
Fig. 5c and Supplementary Data 4). Notably, 421 (19%, hg.t., P <
7.044E-10) and 1431 (21%, hg.t., P < 1.088E-53) bound genes in
K562 and HL60 cells, respectively, also showed differential
ATAC-Seq peaks in zebraﬁsh. GO, IPA, Cytoscape, and GREAT
analyses revealed that, similar to zebraﬁsh, HLX directly regulates
basic cellular processes, including metabolic pathways (Supple-
mentary Fig. 5d and Supplementary Data 4). IPA analyses in
K562 and HL60 cells demonstrated that HLX regulates
mitochondrial and PPAR/RXR pathways (Fig. 4a). Indeed,
multiple ETC genes, but also PPARδ, were directly bound by
HLX in either or both cell types on regions with characteristics of
enhancers as indicated by H3K4me1 and other histone marks
(Fig. 4b and Supplementary Data 4). We conﬁrmed these results
by ChIP-qPCR on independent ChIP experiments with FLAG-
tagged or HA-tagged constructs (Fig. 4c). We also performed
ChIP-qPCR for HLX target genes on K562 cells carrying an
endogenous 3xTy tag on the HLX gene (Fig. 4d). Deletion of one
of the bound regions in the vicinity of the ATP11b gene using
CRISPR-Cas9 technology conﬁrmed that HLX-bound regions can
affect gene expression (Supplementary Fig. 5e). Binding motifs for
multiple transcription factors were identiﬁed in both K562 and
HL60 cells (Fig. 4e and Supplementary Data 4). Importantly,
independent motif analysis uncovered motifs for homeobox
containing factors such as HMBOX1 (Fig. 4e and Supplementary
Data 4). To unravel the chromatin landscape around the HLX-
bound genomic regions, we analyzed available K562 chromatin
data from the ENCODE database38. HLX-bound genomic regions
were located mostly on open chromatin and active enhancers, as
indicated by co-localization with active histone marks (Fig. 4f).
Next, we asked whether HLX binding is associated with
changes in gene expression in human hematopoietic cells. To this
end, we knocked out HLX in K562 cells using CRISPR-Cas9
technology and performed RNA-Seq analysis (Supplementary
Fig. 5f). We found that 1324 genes were downregulated and 600
genes were upregulated in HLX knockout cells (>2-fold change,
NBT, P < 0.05, Fig. 4g and Supplementary Data 5). Two hundred
eighty-four (hg.t., P < 9.874E-25) and 731 (hg.t., P < 4.460E-34)
deregulated genes were directly bound by HLX in K562 and HL60
cells, respectively (Supplementary Data 4). Expression of some
ETC genes bound by HLX was increased, whereas that of PPARδ
was decreased, consistent with our results in zebraﬁsh (Fig. 4h).
Additionally, we performed qPCR for ETC and PPARδ genes in
K562 cells stably overexpressing an inducible HLX construct.
These experiments showed that increased HLX expression leads
to high PPARδ expression with concomitant lower expression of
ETC genes (Supplementary Fig. 5g).
Here, we show that HLX directly regulates ETC and PPARδ
gene transcription, and that this function is conserved from
zebraﬁsh to humans. These exciting results suggest that HLX
controls myeloid differentiation, at least partly, through metabolic
Fig. 2 hlx1 regulates the transcription of metabolic genes. a Heatmap of z-transformed normalized gene expression values from RNA-Seq performed on
sorted endothelial/hematopoietic (ﬂi:kaede+) cells from ﬂi:hHLXOE embryos or endothelial cells (kdrl:GFP+) from hlx1MO at 48 hpf after unsupervised
hierarchical clustering with Euclidean distance metric (see also Supplementary Data 1). b IPA analysis of deregulated genes in the RNA-Seq data from ﬂi:
hHLXOE or hlx1MO embryos at 48 hpf (NBT, P≤ 0.05 and ≥2 fold change) (also see Supplementary Data 1). cMean density plots of read distribution of lost
and gained ATAC-Seq peaks between control and hlx1MO (see also Supplementary Data 2). d Digital genomic footprinting analysis showing average
normalized Tn5 insertion proﬁles around footprinted motifs in merged ATAC peaks as indicated for control and hlx1MO (co-occurrence enrichment
computation, z= 3.583 and z= 13.241, respectively). Insertions on the forward and reverse strands are indicated in red and blue, respectively. The numbers
of motifs are indicated at the bottom of each panel. e Representative gene tracks from ATAC-Seq data of ETC and ppardb genes. f Heatmap of ETC gene
expression in hlx1MO or ﬂi:hHLXOE compared to control from the RNA-Seq analysis. All represented genes show differential chromatin accessibility in
ATAC-Seq. g–i qPCR analysis of selected ppar genes in g endothelial cells from hlx1MO (data representative of two independant experiments, mean+ s.d.)
or (h) whole ﬂi:hHLXOE embryos at 48 hpf (n= 3, mean+ s.d., Student’s t-test, *P < 0.05) or (i) whole Runx:hHLXOE embryos at 5 dpf (n= 2, mean+ s.d.)
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regulation. The combination of high PPARδ expression with low
respiratory chain activity resembles the effects of pathways
involved in controlling LT-HSC stemness28,29,32 and could
explain why HLX-overexpressing cells fail to terminally
differentiate.
HLX overexpression leads to elevated AMPK and autophagy.
HLX is particularly highly expressed in M4 and M5 AML leu-
kemias21. We therefore selected THP1 cells deriving from a
patient with AML (M5 subtype) to further explore the metabolic
function of HLX. ChIP in HLX-overexpressing THP1 cells
revealed that HLX binds to 5827 genes (Supplementary Data 4).
HLX was often found bound to intronic (42.24%) and intragenic
(44.7%) regions, and speciﬁcally to ETC and PPARδ genes
(Fig. 5a). HLX peaks were enriched for H3K27ac, a marker of
active enhancers and promoters (Fig. 5b). Comparison of HLX
ChIP in K562, HL60, and THP1 cells showed that 745 (12.8%, hg.t.,
P < 7.838E-46) and 1767 (30%, hg.t., P < 6.676E-18) of genes
bound by HLX in THP1 cells were also bound in K562 and HL60
cells, respectively. To investigate whether the bound regions of
HLX in THP1 cells represent open chromatin regions in HSCs
and/or preleukemic and leukemic HSCs of AML patients, we used
publicly available ATAC-Seq data39 and selected randomly one
donor for each condition. Strikingly, all HLX-bound regions fall
into accessible chromatin regions in HSCs, pre-leukemic, and
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leukemic HSCs (Fig. 5c). Thus, it is possible that perturbation of
HLX binding affects genes implicated in HSCs or leukemic
transformation.
Consistent with our previous results, ETC genes were down-
regulated and PPARδ was upregulated at the protein level in
THP1 cells (Fig. 5d). Moreover, maximal respiratory capacity was
reduced, and lower levels of reactive oxygen species (ROS) were
produced, in HLX-overexpressing THP1 cells (Fig. 5e, f). As
PPARδ is a well-established regulator of fatty acid metabolism, we
performed carbon tracing in control and HLX-overexpressing
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THP1 cells cultured with13C-glucose. Indeed, we found increased
incorporation of glucose-derived carbon in citric acid that can be
used to produce fatty acids, which was also reﬂected in palmitic
acid, fatty acid C18, and stearic acid (Supplementary Fig. 6).
To uncover the mechanisms downstream of ETC gene
downregulation by HLX, we took a candidate approach and
examined the AMPK pathway. It has recently been proposed that
mitochondrial dysfunction can lead to AMPK activation40.
Moreover, AMPK is a well-established sensor of metabolic stress
and its activation results in elevated autophagy41,42. We found
that AMPKα and phospho-AMPKα (p-AMPKα) are upregulated
in HLX-overexpressing THP1 cells (Fig. 5d). Additionally, the
protein levels of LC3-II, an autophagosome marker, are markedly
increased in these cells upon chloroquine treatment (Fig. 5g).
Together, these results suggest that HLX overexpression in
AML cells affects mitochondrial metabolism and fatty acid
synthesis possibly through the upregulation of PPARδ gene
expression. Additionally, HLX overexpression, possibly through
downregulation of ETC genes, results in AMPK activation and
autophagy.
HLX regulates the metabolic state of CD34+ human cells. Our
ﬁndings could have important implications for patients with
hematopoietic disorders, including AML. We therefore per-
formed colony-forming unit (CFU) assays on human CD34+
HSPCs to measure the effects of HLX modulation in normal
hematopoiesis. Consistent with our zebraﬁsh results and with
published data on mouse HSPCs21, HLX knockdown (sh-HLX)
caused a signiﬁcant reduction in the number of hematopoietic
colonies, whereas HLX overexpression (CD34+ HLX) caused the
opposite phenotype and large myeloid colonies (Fig. 6a, b and
Supplementary Fig. 7a). Culturing CD34+ HLX in myeloid dif-
ferentiation media resulted in a maturation block, as revealed by
the accumulation of early granulocyte-monocyte progenitors
(early GMPs) and the relatively reduced numbers of mature
monocytes and granulocytes (Fig. 6c and Supplementary Fig. 7b).
To assess whether PPARδ and ETC genes are regulated by HLX in
CD34+ cells, we performed RNA-Seq experiments upon HLX
knockdown or overexpression. Due to the high variability in
primary cells we considered all the genes that have at least 1.5-
fold change independently of P-value. The expression of many
ETC genes was clearly upregulated upon sh-HLX and down-
regulated in CD34+ HLX cells (Fig. 6d and Supplementary
Data 5). Selected targets were validated with qPCR (Supple-
mentary Fig. 7c). Thus, the function of HLX in hematopoiesis and
its target genes are conserved in human primary hematopoietic
cells.
To further determine whether the metabolic function of HLX is
conserved in CD34+ cells, we measured OXPHOS. Similar to
zebraﬁsh, increased levels of HLX in human CD34+ cells led to a
reduction in OCR, particularly spare respiratory capacity (Fig. 6e).
Moreover, although HLX overexpression did not cause signiﬁcant
changes on the OXPHOS to extracellular acidiﬁcation rate
(ECAR, representative of glycolytic rate) ratio, HLX-overexpres-
sing cells tended to have a lower ratio (Supplementary Fig. 7d),
suggesting a metabolic adaptation by engagement of glycolysis.
TMRM staining shows that CD34+ HLX cells have decreased
mitochondrial membrane potential, independently of mitochon-
drial mass (Fig. 6f). However, upon differentiation toward
myeloid cells, CD34+ HLX cells exhibited signiﬁcantly higher
OXPHOS than control cells and a tendency to higher OCR/ECAR
ratio (Supplementary Fig. 7e, f).
Our results in THP1 cells showed that HLX overexpression is
followed by AMPK activation. To determine whether AMPK
activation affects myeloid maturation, we induced differentiation
of human CD34+ HSPCs in the presence or absence of
metformin, an AMPK activator that also blocks mitochondrial
complex I thus mimicking the effect of HLX43. Notably,
metformin induced a myeloid differentiation block in CD34+
cells (Fig. 6g). These results suggest that metabolic manipulation
can indeed be the underlying reason for the hematopoietic
phenotypes caused by HLX deregulation.
We next assessed whether pharmacological modulation of
PPARδ activity rescues the myeloid differentiation phenotypes
caused by HLX. Indeed, treatment with a PPARδ antagonist
relieved the myeloid differentiation block in CD34+ HLX cells
(Fig. 7a). Moreover, the inability of sh-HLX cells to form colonies
in CFU assays was partially rescued by a PPARδ agonist
(L165,041) (Fig. 7b). This agonist also rescued the increased
mitochondrial membrane potential observed in sh-HLX cells
(Fig. 7c). To investigate this further, we identiﬁed genes affected
by HLX and potentially regulated by PPARδ using publicly
available PPARδ-binding data in human macrophages44. We
compared these data to our RNA-Seq from human CD34+ cells
and found that 399 (hg.t., P < 0.006) deregulated genes upon HLX
knockdown that can potentially be bound directly by PPARδ
(Supplementary Data 6). IPA analysis on these genes showed
involvement in FAO I (rtFET, P < 2.26 E-04) and AMPK
signaling (rtFET, P < 5.24 E-03) (Supplementary Data 6).
AMPK inhibition causes reduced viability of AML cell lines. To
investigate the potential role of PPARδ and AMPK in promoting
AML downstream of HLX, ﬁrst, we analyzed the expression levels
of HLX and PPARδ by qPCR in various AML cell lines and one
CML cell line, K562. As expected, THP1, a M5 subtype leukemia,
exhibited the highest levels of HLX expression21 but also PPARδ
expression (Fig. 8a). PPARδ protein was only detectable
in THP1 cells (Fig. 8b). AMPKα and pAMPKα expression
was detected in all cell lines without any noticeable differences
(Fig. 8b). TMRM and autophagy were variable between cell lines
(Fig. 8c, d). Next, we asked whether PPARδ and AMPK inhibitors
could push the AML lines and/or K562 cells toward myeloid
maturation or affect their viability. PPARδ antagonists
(GSK3787) had no signiﬁcant impact on either the viability or the
differentiation of AML cell lines and K562 cells (Fig. 8e). How-
ever, AMPK inhibition with dorsomorphin signiﬁcantly reduced
the viability of all but one (HL60) AML cell lines tested and K562
cells (Fig. 8f). It is important to note that dorsomorphin had only
a mild effect on the viability of CD34+ myeloid progenitor cell
populations (Fig. 8f).
Fig. 4 Direct binding of HLX on metabolic genes. a IPA analysis of K562 and HL60 HLX ChIP-Seq peaks (P-values rtFET, see also Supplementary Data 4).
b Representative gene tracks of HLX-bound genomic regions in K562 and HL60 cells, together with publicly available data for histone modiﬁcations in
K562 cells. c ChIP-qPCR validation of selected HLX peaks in K562 and HL60 cells (n= 2, mean+ s.d.). d ChIP-qPCR validation upon ChIP of the
endogenous 3xTy-tagged HLX in K562 cells (n= 2, mean+ s.d.). e Representative motifs identiﬁed in HLX-bound genomic regions in K562 cells (P-values
binomial test, see also Supplementary Data 4). HOX motif is shown in the frame. f Heatmap of ChIP-Seq signals, comparing HLX-bound regions in K562
cells to publicly available CHIP-Seq data for histone marks in K562 cells from the ENCODE database. CTCF was used as negative control. g Gene
expression in control samples plotted vs. gene expression in HLX KO K562 cells. Differentially expressed genes (>2-fold, NBT, P < 0.05) are colored in red
and blue for upregulated and downregulated genes, respectively (also see Supplementary Data 5). h Average expression levels of selected genes from
RNA-Seq of K562 HLX KO cell line (Student’s t-test, *P < 0.05, ***P < 0.001)
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Thus, we show here that AMPK inhibition decreases
the viability of AML cell lines. Our study depicts HLX as a
novel metabolic regulator in both normal and malignant cells
(Fig. 8g).
Discussion
Recent evidence showing that the H2.0-like HLX is implicated in
many malignancies highlights the importance of understanding
the function and identifying the targets of this transcription
factor21,45,46. In agreement with previous reports21, in the present
study we demonstrate in zebraﬁsh models that HLX affects
myeloid differentiation, and we recapitulate these results in
human HSPCs for the ﬁrst time. We provide evidence that this
regulation occurs, at least partly, through direct modulation of
metabolic pathways by HLX. Speciﬁcally, we show that HLX
directly regulates several metabolic genes, including PPARδ and
genes of the mitochondrial ETC. In agreement with our results, it
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was recently shown by Huang et al. that HLX controls a sys-
tematic switch from white to brown fat through metabolic gene
regulation, including PPARs and genes that control mitochon-
drial biogenesis24. However, in that study HLX was found to
positively regulate both mitochondrial biogenesis and PPARs, in
contrast to our study where ETC genes are downregulated upon
HLX overexpression. It will be interesting to study whether
diverse HLX-interacting partners could account for these
differences.
Recently, metabolism has emerged as a critical regulator of
HSCs. LT-HSCs are quiescent and rely mostly on anaerobic
glycolysis rather than OXPHOS47,48. A number of studies have
shown that low mitochondrial activity is necessary to maintain
the quiescent state and the self-renewal capacity of LT-HSCs and
protect them from oxidative stress28,49–53. The importance of
reduced mitochondrial activity for HSC maintenance has also
been demonstrated in human CD34+ HSPCs54–56. Antagonism
of PPARγ signaling enhances glycolysis and leads to expansion of
human HSPCs57. Moreover, recent evidence revealed that
PPARδ, a regulator of fatty acid metabolism, plays an essential
role in maintaining HSC stemness by regulating mitophagy and
promoting HSC asymmetric cell divisions32,58. During differ-
entiation, PPARδ signaling is downregulated leading to a gradual
increase in mitochondrial mass and symmetric commitment of
HSC daughter cells32. Thus, PPARδ, but also HLX that controls
its expression, may constitute a metabolic switch for regulating
HSC cell fate. It is interesting to speculate, based on our results,
that HLX is a gatekeeper of HSC identity by maintaining their
glycolytic state. We also show that HLX overexpression leads to
low spare respiratory capacity, a characteristic of AML cells59.
Both these results could be used in the future to better understand
the implication of HLX in AML. However, since both HLX and
PPARδ exert many functions besides metabolic regulation, we
need to fully understand the precise mechanisms underlying our
rescue experiments by PPARδ modulation. Interestingly, since
PPARδ, like HLX, is overexpressed in a subset of M5 type-
monoblastic AML cases60, it is conceivable that PPARδ inhibi-
tion could play a role in AML. Our results do not support this
hypothesis, but further investigations should shed more light on a
potential role of PPARδ in AML.
Also of note, we show that metformin, which blocks mito-
chondrial complex I and activates AMPK43, thereby mimicking
the metabolic function of HLX, can affect myeloid differentiation.
This ﬁnding proves that metabolic regulation can indeed be the
direct mediator of HLX functions and, at least in part, causative
for the phenotype. Metformin has been used as an anticancer
therapy in many malignancies, including AML61. Based on our
ﬁndings, it is pertinent to fully understand the role of metformin
in physiological and pathological conditions.
Finally, we found that HLX overexpression leads to activation
of AMPK. AMPK does not seem to play a role in HSCs during
homeostasis, transplantation, or under metabolic stress62, but
protects leukemia initiating cells from metabolic stress63. This
suggests AMPK as an ideal potential target for the treatment of
leukemia without affecting normal cells. Indeed, we found that
AMPK inhibition has a strong effect on the survival of AML cell
lines. AMPK inhibition is also successful in eliminating MLL-
rearranged B-cell acute lymphoblastic leukemia64. However, other
studies suggest that AMPK acts synergistically with mTORC1 and
causes lethality in AML cells65. Further research with samples
from human patients and speciﬁc mouse models are needed to
clarify these discrepancies.
Our study points to differential requirements and regulatory
mechanisms between normal and leukemic cells by the same
transcription factor and identiﬁes HLX as a new player in
metabolic regulation in hematopoiesis.
Methods
Zebraﬁsh maintenance. The zebraﬁsh (D. rerio) strain Tübingen (Tü) and all
zebraﬁsh transgenic lines used in this study were maintained in the animal facility
of the Max Planck Institute of Immunobiology and Epigenetics. The sample size for
the animal experiments was chosen according to the following paper66. No animals
were excluded from this study and no randomization was used. Only 1–5 dpf
embryos were used in this study and sex was not determined at these stages. All
animal experiments were performed in accordance with relevant guidelines and
regulations, approved by the review committee of the Max Planck Institute of
Immunobiology and Epigenetics and the Regierungspräsidium Freiburg, Germany
(license Az 35-9185.81/G-14/95).
Zebraﬁsh morpholino injections and rescue experiments. Embryos were
injected (PV820 Pneumatic PicoPump, World Precision Instruments) at the one-
cell stage with 8 ng of standard morpholino or 8 ng of hlx1 translational or 12 ng
splicing anti-sense morpholino that have been previously described26 (Gene Tools,
Philomath, OR). Stock solutions were diluted as recommended by the manu-
facturer. The sequence for the hlx1 translational anti-sense morpholino: 5′-
AGCCGAACAATACGCAGTCCACAGG-3′; splicing anti-sense morpholino: 5′-
GATTAAATTAGCGTCTTACCTCTCA-3′; standard oligo: 5′-CCTCTTACCT
CAGTTACAATTTATA-3′.
For the rescue experiments one-cell stage Tg(Runx:mCherry)27 embryos were
injected with 12.5 or 25 pg of ﬂi:HLX or Runx:HLX constructs followed by injection
of hlx1 morpholino as described above. Injected embryos were grown until 72 hpf,
manually dechorionated and embedded in 1% low melting agarose, containing
0.04 mg/mL tricaine. Caudal hematopoietic tissue was imaged using Zeiss
Apotome2 microscope at 10× magniﬁcation. Flow cytometry of mCherry-positive
cells is described in the section “Preparation of zebraﬁsh cells, ﬂow cytometry, and
cell sorting”. WISH staining and analysis, constructs and generation of transgenic
zebraﬁsh lines are described in Supplementary Material and Methods.
Preparation of zebraﬁsh cells, ﬂow cytometry, and cell sorting. Embryos were
incubated in 0.5 mg/mL Liberase TM (Roche) solution for 30 min at 37 °C, then
dissociated and resuspended in PBS-5% fetal bovine serum (FBS), and used for cell
sorting, ﬂow cytometry, seahorse assay, qPCR, and RNA-Seq experiments. Cell
sorting was performed using Inﬂux (BD Biosciences). For all experiments cell-
sorting purity was over 85%.
May–Grünwald–Giemsa staining of zebraﬁsh blood. For CHT smears, 48 hpf
(ﬂi:hHLXOE) or 5 dpf (Runx:hHLXOE) embryos were placed in 0.9% NaCl with
0.04 mg/mL tricaine and the tails were isolated at the level of the cloaca/end of the
yolk sac extension and incubated with Liberase TM (at 1:65 dilution in 0.9% NaCl,
Roche) with 0.04 mg/mL tricaine for 20 min at 37 °C. FBS was then added to a ﬁnal
concentration of 10%, to stop enzymatic digestion. The tails were triturated and
then passed through a 40 µM mesh ﬁlter. The smears of dissociated cells were
prepared by cytospin followed by May–Grünwald–Giemsa staining. Cells were
imaged using Zeiss Axio Imager microscope with 100× objective.
Fig. 5 AMPK and autophagy activation in HLX-overexpressing cells. a Representative gene tracks of HLX and H3K27ac-bound genomic regions in THP1 cells.
Location annotation of HLX-bound regions across the genome. b Heatmap of ChIP-Seq signals comparing HLX-bound regions to H3K27ac regions in
THP1 cells. c Heatmap comparing HLX-bound regions in THP1 cells to ATAC-Seq regions of HSCs, pre-leukemic HSCs, and leukemic HSCs. d Western blot
analysis of HA-HLX, PPARδ, AMPKα, and p-AMPKα, mitochondrial ETC complexes and Histone 3 (H3) as loading control. Cells were untreated or treated
with doxycycline for 24 h to induce HLX expression. Representative immunoblots of at least three independent experiments. Quantiﬁcations were performed
by FIJI software software and are shown below the blots as a ratio to H3. The ﬁve OXPHOS complexes are depicted as C-I to V. e Oxygen consumption rate
(OCR) in control or HLX-overexpressing THP1 cells. Representative plot from three independent experiments (mean ± s.d.). f Bar graph depicting
mitochondrial ROS production in control and THP1-HLX cells (n= 3, mean+ s.d., Student’s t-test, **P < 0.01). g Western blot analysis of LC3-II, HA, and H3
in control and THP1-HLX cells non-induced, induced with Doxycycline (Dox) with or without the addition of Chloroquine (CQ). Representative immunoblots
of three independent experiments. Quantiﬁcation was performed by Fiji software and is shown below the blot as a ratio to H3
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TUNEL assay. Whole-mount TUNEL staining of developmentally staged control,
morphant, and overexpression embryos was performed using the in situ cell death
detection kit with ﬂuorescein (Roche Applied Science, 11684795910). Embryos
were then embedded in 1% low melting agarose and imaged with a Zeiss LSM780
confocal microscope and a 10× objective.
EdU labeling. Cell proliferation in zebraﬁsh was assayed using the Click-iT EdU
Alexa Fluor 647 Imaging Kit (Thermo Fisher Scientiﬁc). Brieﬂy, zebraﬁsh embryos
at 48 hpf were dechorionated and incubated with Liberase TM as described in the
section “Preparation of zebraﬁsh cells, ﬂow cytometry, and cell sorting”.
Dissociated cells were spun down, resuspended in EdU staining solution, and
incubated for 30 min at 37 °C. Cells were ﬁxed and permeabilized, followed by EdU
detection reaction, according to the manufacturers’s instructions. Cells were then
analyzed by ﬂow cytometry (BD LSRFortessa).
Cell line and primary cell maintenance. K562 and SKNO1 cells were maintained
in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM, Gibco) supplemented with 10%
FBS (Sigma, F7524) and 1% Penicillin Streptomycin (P/S, 100 U/mL penicillin with
100 μg/mL streptomycin, Gibco). KG1 cells were maintained in IMDM 20% FBS,
1% P/S. HL60, NB4, and THP-1 cells were maintained in RPMI 1640 medium
a
0 20 40 60 80
0
200
400
600
CFU-C per 500 cells
GEMM 
GM 
G 
M 
BFUE 
b
27 
8,8
44 
8,3
0
10
20
30
40
50
60
70
80
90
100
CD34+
scrRNA 
GEMM
GM
G
M
BFUE
N
um
be
r o
f c
ol
on
ie
s
CFU-C per 500 cells
d
CD34+
sh-HLX
****
e
6.24.4 
33.4
17.2 
18.2
17.6 
0
10
20
30
40
50
60
70
*
N
um
be
r o
f c
ol
on
ie
s
GEMM 
GEMM BFU-E 
GEMM M 
M 
g
Fold change
0.1 37
c CD34+ differentiation toward myeloid (7 d.)
Fo
ld
 e
nr
ich
m
en
t
0
20
40
60
80
**
Metformin
10 μM
+–
**
+– +–
Early GMPs/
monoblasts
Mature Mon.
and Gran.
Macrophages
m
tD
N
A/
nD
NA
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8 n.s.
ATP5O
ATP5A1
ATP5B
ATP5C1
ATP5F1
ATP5G3
COX5A
COX6C
COX7A2
NDUFA1
NDUFA4
NDUFA5
NDUFA6
NDUFAB1
NDUFB3
NDUFB4
NDUFB5
NDUFB6
NDUFB8
NDUFC2
NDUFS1
NDUFS2
PPARD
PPA1
PPA2
Co
m
pl
ex
V
Co
m
pl
ex
I
Co
m
pl
ex
IV
%
 c
el
ls
0.0
0.5
1.0
1.5
2.0
Early GMPs/
Monoblasts
Mature Mon.
and Gran.  
Macrophages 
**
*
n.s.
f
0
0.5
1.0
M
FI
 H
LX
/G
FP
***
CD34+
GFP
CD34+
HLX
CD34+GFP
CD34+HLX
Oligomycin FCCP Rot./Ant. A
O
CR
 (p
mo
les
/m
in)
Time (min)
CD34+
GFP
CD34+
HLX
CD34+GFP
CD34+HLX
CD34+
GFP
CD34+
HLX
CD34+
GFP
CD34+
HLX
WT CD34+ differentiation toward myeloid (7 d.)
CD34+
sh-HLX
CD34+
HLX
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05311-4
12 NATURE COMMUNICATIONS |  (2018) 9:3090 | DOI: 10.1038/s41467-018-05311-4 | www.nature.com/naturecommunications
a0
2000
4000
6000
8000
M
FI
 (T
MR
M)
*
*
c
b
0
50
100
150
N
um
be
r o
f c
ol
on
ie
s 
(pe
r 3
00
0 c
ell
s)
GEMM 
GM 
G 
M 
BFUE 
Vehicle L165,041 
n.s.
***
125 
65 
13 7 
127.7 
70.3 
12.7 
40.7 
20 
HLX  OE
Ctrl
n.s
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
CD34+ scrRNA
m
tD
N
A/
nD
NA
n.s. *
n.s.
GSK3787 – – + + – – + + – – + +
0
20
40
60
80
%
 o
f c
el
ls *
*
*
n.s.
Early GMPs/
monoblasts
Mature monocytes
and granulocytes
Macrophages
Rescue of CD34+ differentiation toward myeloid (7 d.)
CD34+
scrRNA 
CD34+
sh-HLX
CD34+
GFP
CD34+
HLX
CD34+ shHLX
Vehicle L165,041 Vehicle L165,041 
CD34+ scrRNA
CD34+ shHLX
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block after treatment (n= 3, Student’s t-test, *P < 0.05, mean+ s.d.). b Average number of colonies in CFU-C assays performed in CD34+ cells infected
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Fig. 6Metabolic role of HLX in human CD34+ cells. a Average number of colonies in CFU-C assays performed in CD34+ cells infected with control scrRNA
or sh-HLX (left panel) or in CD34+ cells overexpressing GFP (CD34+ GFP) or HLX (CD34+ HLX) (right panel) (n= 3, three technical replicates each time,
mean+ s.d., Student’s t-test, *P < 0.05, ****P < 0.0001). GEMM Granulocyte, Erythrocyte, Monocyte, Megakaryocyte, GM Granulocyte, Macrophage, G
Granulocyte, M Macrophage, BFUE Burst-forming unit-erythroid. b Representative images of GEMM, BFUE, and M colonies from CFU-C assays in CD34+
GFP or CD34+ HLX cells. Scale bar: 50 µM. c Flow cytometric analysis representing elevated numbers of immature myeloid cells in CD34+ HLX cells
differentiated toward the myeloid lineage for 7 days (n= 3+ s.d., Student’s t-test, *P < 0.05, **P < 0.01). d Heatmap representing the fold change of
selected genes from RNA-Seq of CD34+ sh-HLX and CD34+ HLX cells compared to their respective controls. e Oxygen consumption rate in CD34+ GFP or
HLX cells before differentiation (n= 3, mean+ s.d.). f Mitochondrial membrane potential measured by TMRM in CD34+ GFP or CD34+ HLX cells (left
panel) (n= 6, mean+ s.d., Student’s t-test, ***P < 0.001) and the corresponding mitochondrial vs. nuclear DNA ratio (right panel) (n= 3, mean+ s.d.,
Student’s t-test n.s.). g Flow cytometric analysis representing numbers of immature myeloid cells upon addition of metformin to wild-type CD34+ cells
cultured in myeloid differentiation media for 7 days (n= 3, mean+ s.d., Student’s t-test, **P < 0.01)
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Fig. 8 AMPK inhibition causes lethality in AML cell lines. a qPCR expression analysis of HLX and PPARδ in AML cell lines and K562 cells (n= 2, mean+ s.e.m.).
b Representative western blot analysis for PPARδ (n= 4), AMPKα (n= 3), p-AMPKα (n= 2) and H3 as loading control in different AML cell lines and
K562 cells. Quantiﬁcations shown below the panels, as a ratio to H3, were performed by FIJI software. c Mitochondrial membrane potential measured by
TMRM in AML cell lines and K562 cells. MFI median ﬂuorescence intensity (representative of two independent experiments, mean+ s.d.). d Flow
cytometry analysis of autophagic ﬂux in different AML cell lines and K562 cells incubated with DMSO or chloroquine. MFI median ﬂuorescence intensity
(representative of two independent experiments, mean+ s.d.). e Measurement of viable cells (left panel) or CD11b staining as a marker of myeloid
differentiation (right panel) with or without the PPARδ antagonist GSK3787 (n= 5, mean+ s.d.). fMeasurement of viable cells after incubation of different
AML cell lines and K562 cells or WT CD34+ cells with or without dorsomorphin (n= 3, mean+ s.d., Student’s t-test, **P < 0.01, ****P < 0.0001). g Model
of HLX function in hematopoiesis
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(Gibco) supplemented with 10% FBS, 1% P/S. Kasumi cells in RPMI 1640 medium
with 20% FBS, 1% P/S. The cell line OCI-AML3 was maintained in Alpha MEM
(Gibco) supplemented with 20% FBS, 1% P/S. All media were supplemented with
2 μM glutamine. K562 cells were veriﬁed from Euroﬁns and from RNA-Seq
experiments and THP1 cells veriﬁed by next generation sequencing experiments.
Cell lines were mycoplasma free as tested by qPCR. Cell lines were purchased from
Sigma or ATCC or Lonza. Cell line generation and constructs can be found in the
Supplementary Information.
Human CD34+ cells, isolated from the peripheral blood of granulocyte colony-
stimulating factor mobilized healthy volunteers, were purchased from the Fred
Hutchinson Cancer Research Center. The cells were maintained as previously
described67. Brieﬂy cells were cultured in StemSpan SFEM (StemCell
Technologies), supplemented with 2% P/S and cytokine mix: m-SCF 100 ng/mL,
hFLT3 100 ng/mL, hIL-3 20 ng/mL, and hIL-6 20 ng/mL (expansion medium).
Cells were kept at 1 × 105–1 × 106 cells/mL densities.
Lentiviral particle production. 293T cells were transfected with lentiviral plasmids
(packaging vectors with GFP-HA or HLX-HA or sh-HLX or scrRNA) mix using
the polyethylenimine (PEI) method. Brieﬂy, 2 h before the transfection, fresh 2%
FBS containing medium was added. For 9 cm culture dishes, 5 μg of total DNA mix
(construct, pPAX2, and pMDG.2 were used at a ratio of 10:7.5:3, respectively) was
diluted with plain DMEM (Gibco) up to 520 μL. 30 μL of 1 mg/mL PEI reagent was
then added and the mix was vortexed shortly twice. The mix was incubated for
10 min at RT before adding drop wise to 293T cells. The medium was changed after
8 h. Supernatants containing lentiviral particles were collected at 48, 72, and 96 h
post transfection and concentrated using Lenti-X concentrator (TAKARA). All
lentiviral experiments were performed in S2 laboratory with permission from
German authorities: Regierungspräsidium Tübingen (57-3/8817.40-020).
Electroporation or infection of CD34+ cells. HLX overexpression: 1 day after
thawing, 1 million cells were electroporated using the Human CD34+ Cell
Nucleofector kit (Lonza) with 5 μg pCMV6-AC-HLX (Origene, NM_021958) or as
a control 5 μg of pEGFP-C1 plasmids. A day after electroporation CD34+ GFP and
HLX cells were selected with neomycin (0.8 mg/mL) and expanded for 4 more
days.
HLX knockdown: To generate shRNA against HLX (sh-HLX), we cloned
annealed oligos (Supplementary Table 1) into the pLKO.1-TCR vector (a gift from
David Root; Addgene plasmid #10878) digested with AgeI and EcoRI. As a control,
a non-hairpin pLKO.1-TCR control (scrRNA) (a gift from David Root; Addgene
plasmid #10879)68 was used. For the generation of scrRNA and shHLX, human
CD34+ cells were infected after 1-day expansion in expansion medium (see section
“Cell line and primary cell maintenance”). Cells were placed on retronectin-coated
(TAKARA) plates and transduced with concentrated virus at a multiplicity of
infection of 5 in expansion medium. Cells (1 × 106 cells/mL; 1 mL per well in 6-well
plates) were transduced three times using spinoculation (6 μg/mL polybrene, 800 × g,
90min) at 6–12 h intervals for 2 consecutive days. Then cells were washed ﬁve times
in PBS and transefered in expansion medium containing puromycin (1 μg/mL) for 3
more days.
CFU-C assays. The CFU-C assays were performed by plating 500 or 3000 CD34+
cells per plate in CFU-C media (R&D Systems, HSC003), according to the man-
ufacturer’s instructions. Colonies consisting of at least 40 cells were counted after
15 days at 37 °C and 5% CO2. CFU-C colonies were counted blindly regarding
control and experimental samples.
Myeloid differentiation. Myeloid lineage-speciﬁc CD34+ differentiation was
carried out by culturing the cells in expansion media supplemented with 20 ng/mL
GM-CSF (Peprotech, ref. 300-03). Cells were cultured at 1 × 105–1 × 106 cells/mL
densities and analyzed on day 7 and day 14, using CD34+-PerCP-Cy5.5 (1:60,
clone 561), CD11b-PE-Cy7 (1:60, clone ICRF44), CD14-AlexaFluor700 (1:200,
clone 63D3), CD16-APC (1:40, clone B73.1), and CD33-PE conjugated antibodies
(1:60, clone P67.6) (all from BioLegend). Myeloid differentiation of AML cell lines
was assessed using CD11b-PE-Cy7 (1:60, Biolegend clone ICRF44).
Cell viability. Viability was assessed by ﬂow cytometry after staining with Hoechst
33258 (Life Technologies, 1 µg/ml; ref. H3569) in PBS supplemented with 2% FBS
and 1mM EDTA. After 20 min, cells were analyzed in a cell analyzer (BD,
LSRFortessa). Viable cells were determined by Hoechst staining exclusion and
quantiﬁed using FlowJo software (Tree Star, Inc.).
Pharmacological treatments. Zebraﬁsh: For pharmacological treatment, embryos
were manually dechorionated and incubated with the PPARδ agonist L165,041
(Cayman Chemical, ref. 9000249; 500 nM) or antagonist GSK3787 (BioVision, ref.
2400; 500 nM) from the 18 somite stage to 48 or 72 hpf.
Cells: For mitochondrial membrane potential rescue experiment CD34+
scrRNA and sh-HLX cells were treated with vehicle (DMSO) or 100 nM PPARδ
agonist L165,041, while CD34+ GFP and HLX were treated with vehicle (DMSO)
or 300 nM PPARδ antagonist GSK3787 for 21 h. For the CD34+ differentiation
experiments, cells were treated with 300 nM antagonist GSK3787 (BioVision, ref.
2897-5), or 5 µM Dorsomorphin hydrochloride (Enzo, ref. ENZ-CHM141) for the
last 48 h of the 7-day differentiation protocol, or 10 µM Metformin hydrochloride
(Sigma, ref. PHR1084) for the last 4 days of the 7-day differentiation. For the HLX
knockdown rescue experiments scrRNA and shHLX cells were treated with 100 nM
PPARδ agonist L165,041 for 7 days. Leukemic cell lines were treated for 48 h with
1 μM PPARδ antagonist GSK3787, or 5 µM Dorsomorphin.
Detection of autophagic ﬂux. Autophagy was measured using the Cyto-ID®
Autophagy detection kit (Enzo, ref. ENZ-51031), according to the manufacturer’s
instructions. Brieﬂy, cells were grown at a density of 1 × 106 cells/mL for 16 h at
37 °C, in the presence of DMSO or Chloroquine (60 µM). Cells were washed with
PBS, pelleted at 1000 rpm for 5 min, and incubated with cyto-ID green reagent for
30 min at 37 °C in the dark prior to ﬂow cytometry analysis on LSRFortessa cell
analyzer (BD Biosciences). Mean ﬂuorescence intensity (MFI) was quantiﬁed using
FlowJo software (Tree Star, Inc.).
Real-time qPCR. Total RNA was extracted from human or zebraﬁsh cells using the
RNA Clean & Concentrator-5 kit (Zymo Reasearch) kit or TRI Reagent, according
to the manufacturer’s instructions. cDNA was prepared with the SuperScript™
First-Strand Synthesis System for RT-PCR kit (Thermo Fisher Scientiﬁc). qPCR
reactions were executed using Fast SYBR green Master Mix (Thermo Fisher Sci-
entiﬁc) in a StepOnePlus Real-Time PCR machine (Applied Biosystem). Expres-
sion was plotted relative to RAB7 (for human cells) and cyyr1 (for zebraﬁsh cells).
All qPCR graphs in this study are representative of at least two independent
experiments. qPCR primers can be found in Supplementary Table 2.
Metabolic assays. OCR and ECAR were measured using a 96-well XF or XFe
extracellular ﬂux analyzer (Seahorse Bioscience) in XF media (non-buffered RPMI
medium 1640 containing 25 mM glucose, 2 mM glutamine, and 1 mM sodium
pyruvate) containing the cytokine mix of expansion medium for CD34+ experi-
ments or 10% FBS for zebraﬁsh experiments. The measurements were performed
under basal conditions and in response to 1 μM oligomycin, 1.5 μM FCCP, and
100 nM rotenone combined with 1 μM antimycin A.
Glucose tracing. For metabolic tracing THP1 cells were cultured in glucose-free
RPMI media with dialyzed serum supplemented with 11 mM D-[U13C] glucose
and 2% P/S for 24 h. Cells were washed with ice cold 0.9% w/v NaCl buffer and
metabolites were extracted twice with hot ethanol (70%) and analyzed by GC mass
spectrometry (GCMS). Fractional contribution from exogenous substrates was
calculated as described previously69. Brieﬂy, metabolite extracts were dried,
resuspended in pyridine, and derivatized with methoxylamine and N-tert-Butyl-
dimethylsilyl-N-methyltriﬂuoroacetamide with 1% tert-Butyldimethylchlorosilane
before GCMS analysis on an Agilent 7890 GC with Agielnt 5977 MS. Peak areas of
all possible labeling states were extracted for full-carbon-backbone fragments of
selected metabolites to obtain mass distribution vectors (MDVs). MDVs were then
corrected for natural abundance of heavy isotopes by constrained optimization of
the linear equation
I ¼ L M;
where I denotes the measured fractional abundance of metabolite fragments of
different labeling states, L denotes the correction matrix, and M denotes the cor-
rected MDV69. The fractional contribution from exogenous substrates was then
calculated as the weighted average of the MDV
FC ¼
Pn
i¼0 i  si
n
;
where FC denotes the fractional contribution, i is the position in the MDV, si is the
value of the MDV at the position i, and n is the length of the MDV. All calculations
were implemented in an in-house R script.
Mitochondrial membrane potential and mtDNA/nDNA measurement. Zebra-
ﬁsh cells or human cells were stained with tetramethylrhodamine, methyl ester
(Image-iT™ TMRM Reagent, Invitrogen, ref. I34361; 50 nM) at 28 or 37 °C,
respectively, for 30 min, then washed with PBS-5% FBS and analyzed by ﬂow
cytometry with LSRFortessa or LSR II cell analyzers (BD Biosciences). MFI was
quantiﬁed using FlowJo software (Tree Star, Inc.). To measure the ratio of mito-
chondrial and nuclear DNA (mtDNA/nDNA), genomic DNA was extracted from
105 cells using DNeasy Blood & Tissue Kit (Qiagen) and real-time qPCR was
performed as described before70. Brieﬂy, quantitative PCR reactions were assem-
bled as follows: 2 μL of template DNA (3 ng/μL isolated DNA), 2 μL of mtDNA or
nDNA target-speciﬁc primer pair (400 nM ﬁnal concentration each), 12.5 μL SYBR
Green PCR Master Mix, and 8.5 μL H2O in 1 well of the 96-well PCR plate. All
qPCR experiments were performed in triplicate wells in three independent
experiments. Primer sequences can be found in Supplementary Table 2.
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Reactive oxygen species. ROS were determined by incubating cells with Mito-
SOX™ Red Mitochondrial Superoxide Indicator (Invitrogen, ref. M36008; 5 µM) at
37 °C for 10 min in the dark, then washed with PBS-5% FBS and analyzed by ﬂow
cytometry with LSRFortessa or LSR II cell analyzers (BD Biosciences). MFI was
quantiﬁed using FlowJo software (Tree Star, Inc.).
Western blot. Total cell lysates from all protein samples in this manuscript were
incubated on ice in lysis buffer for 20 min (50 mM Tris, pH 7.5, 150 mM NaCl, 1%
Triton X-100, 10% glycerol, 1 mM EDTA, 1× protease and phosphate inhibitors
(Sigma-Aldrich)) followed by three cycles of 15 s sonication (Bioruptor). Lysates
were subjected to Western blot analysis to detect Ty tag (1:500, SAB4800032
Sigma-Aldrich), Flag tag (1:5000, Sigma-Aldrich, clone M2, F1804), β-actin
(1:10,000, C4, Santa Cruz Biotechnology, sc47778), HA tag (1:1000, Sigma-Aldrich,
3F10, 000000011867423001), H3 (1:10.000, Abcam, ab4729), PPARβ (1:500, Santa
Cruz Biotechnology, F-10, sc-74517), total oxphos (1:2000, Antibody Cocktail,
Abcam, ab110413), AMPKα (1:2000, Cell Signaling Technology, D5A2, 5831), and
phospho-AMPKα T172 (1:2000, Cell Signaling Technology, 40H9, 2535). For
detection of LC3B (1:2000, Cell Signaling Technology, 2775) the cells were addi-
tionally subjected to a 24 h treatment with chloroquine (Sigma-Aldrich, ref. C6628;
25 μM) before lysis. Western blots were either exposed on ﬁlms or scanned with the
BioRad ChemiDoc Touch Imaging System. Uncropped western blots can be found
in Supplementary Fig. 8.
Statistical analysis. Statistical analysis was performed using two-tailed unpaired
Student’s t-test or one-way ANOVA test as indicated in the ﬁgure legends. Sample
sizes and signiﬁcance are shown in the ﬁgure legends. Statistical analysis for the
overlap between gene sets was performed with hypergeometric test and shows the
signiﬁcance of the overlap in each case. Other statistical analyses are described in
the respective sections.
Genome-wide analysis. RNA-Seq libraries, RNA-Seq preparation and analysis
methodology, ATAC-Seq libraries, ATAC-Seq analysis methodology, Chromatin
Immunoprecipitation, ChIP-Seq libraries, ChIP-Seq analysis, gene ontology,
pathway and network analysis, motif analysis, digital genomic footprinting for
ATAC-Seq, network construction, hierarchical differentiation tree can be found in
the Supplementary Information.
Code availability. All computer codes used in this manuscript are available upon
request.
Data availability. All raw sequencing data have been deposited in the Short Read
Archive SRA under the BioProject accession codes PRJNA390228, PRJNA390119,
and PRJNA433488. All the data are available without restrictions.
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